Relmada Therapeutics, Inc. (RLMD) |
| 4.06 -0.05 (-1.22%) 01-13 16:00 |
| Open: | 4.09 |
| High: | 4.21 |
| Low: | 3.91 |
| Volume: | 608,151 |
| Market Cap: | 298(M) |
| PE Ratio: | -2.28 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 4.99 |
| Resistance 1: | 4.58 |
| Pivot price: | 4.39 |
| Support 1: | 3.91 |
| Support 2: | 3.25 |
| 52w High: | 5.12 |
| 52w Low: | 0.24 |
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Financials
| EPS | -1.780 |
| Book Value | 0.280 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -102.4 |
| Return on Equity (ttm) | -196.8 |
Company news
Mon, 12 Jan 2026
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications - Investing News Network
Mon, 12 Jan 2026
Relmada Therapeutics (RLMD) Advances NDV-01 with FDA Guidance - GuruFocus
Mon, 12 Jan 2026
FDA backs new bladder cancer studies for patients with few options left - Stock Titan
Mon, 22 Dec 2025
Relmada Therapeutics (RLMD) Initiates Coverage with Buy Rating | RLMD Stock News - GuruFocus
Mon, 22 Dec 2025
Jefferies initiates Relmada Therapeutics stock with Buy rating on pipeline pivot - Investing.com
Mon, 22 Dec 2025
Jefferies Initiates Coverage of Relmada Therapeutics (RLMD) with Buy Recommendation - Nasdaq
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
